ABSTRACT
Primary sclerosing cholangitis (PSC) is a serious liver disease associated with inflammatory bowel disease (IBD). Galectin-3, an inflammatory and fibrotic molecule, has elevated circulating levels in patients with chronic liver disease and inflammatory bowel disease (IBD). This study aims to clarify whether galectin-3 can differentiate between patients with IBD, PSC, and PSC-IBD. Our study measured serum galectin-3 levels in 38 healthy controls, 55 patients with IBD, and 22 patients with PSC (11 patients had underlying IBD and 11 patients did not), alongside the urinary galectin-3 of these patients and 18 controls. Serum and urinary galectin-3 levels in IBD patients were comparable to those in controls. Among IBD patients, those with high fecal calprotectin, indicating severe disease, exhibited lower serum and elevated urinary galectin-3 levels compared to those with low calprotectin levels. Serum galectin-3 levels were inversely correlated with C-reactive protein levels. PSC patients displayed higher serum and urinary galectin-3 levels than IBD patients, with the highest serum levels observed in PSC patients with coexisting IBD. There was no correlation between serum and urinary galectin-3 levels and laboratory indicators of liver injury in both IBD and PSC patients. In conclusion, this study demonstrates that serum and urinary galectin-3 levels can distinguish IBD from PSC patients, and also reveals higher serum galectin-3 levels in PSC-IBD patients compared to those with isolated PSC.
Subject(s)
Biomarkers , Cholangitis, Sclerosing , Galectin 3 , Inflammatory Bowel Diseases , Humans , Cholangitis, Sclerosing/blood , Cholangitis, Sclerosing/diagnosis , Female , Male , Biomarkers/blood , Biomarkers/urine , Middle Aged , Adult , Galectin 3/blood , Inflammatory Bowel Diseases/blood , Inflammatory Bowel Diseases/diagnosis , Leukocyte L1 Antigen Complex/blood , C-Reactive Protein/metabolism , C-Reactive Protein/analysis , Case-Control Studies , Aged , Galectins/blood , Blood ProteinsABSTRACT
PKGs are serine/threonine kinases. PKG1 has two isoforms-PKG1α and ß. Inositol trisphosphate receptor (IP3R)-associated cGMP-kinase substrate 1 (IRAG1) is a substrate for PKG1ß. IRAG1 is also known to further interact with IP3RI, which mediates intracellular Ca2+ release. However, the role of IRAG1 in PH is not known. Herein, WT and IRAG1 KO mice were kept under normoxic or hypoxic (10% O2) conditions for five weeks. Animals were evaluated for echocardiographic variables and went through right heart catheterization. Animals were further sacrificed to prepare lungs and right ventricular (RV) for immunostaining, western blotting, and pulmonary artery smooth muscle cell (PASMC) isolation. IRAG1 is expressed in PASMCs and downregulated under hypoxic conditions. Genetic deletion of IRAG1 leads to RV hypertrophy, increase in RV systolic pressure, and RV dysfunction in mice. Absence of IRAG1 in lung and RV have direct impacts on PKG1ß expression. Attenuated PKG1ß expression in IRAG1 KO mice further dysregulates other downstream candidates of PKG1ß in RV. IRAG1 KO mice develop PH spontaneously. Our results indicate that PKG1ß signaling via IRAG1 is essential for the homeostasis of PASMCs and RV. Disturbing this signaling complex by deleting IRAG1 can lead to RV dysfunction and development of PH in mice.
Subject(s)
Cyclic GMP-Dependent Protein Kinase Type I/metabolism , Hypertension, Pulmonary/metabolism , Membrane Proteins/deficiency , Animals , Cell Hypoxia , Down-Regulation , Gene Deletion , Heart Ventricles/pathology , Heart Ventricles/physiopathology , Humans , Hypertension, Pulmonary/physiopathology , Lung/pathology , Lung/physiopathology , Membrane Proteins/genetics , Membrane Proteins/metabolism , Mice, Knockout , Myocytes, Smooth Muscle/metabolism , Myocytes, Smooth Muscle/pathology , Pulmonary Artery/pathology , Pulmonary Artery/physiopathology , Vascular RemodelingABSTRACT
Non-alcoholic steatohepatitis (NASH) is characterized by immune cell infiltration. Loss of the scaffold protein alpha-syntrophin (SNTA) protected mice from hepatic inflammation in the methionine-choline-deficient (MCD) diet model. Here, we determined increased numbers of macrophages and CD8+ T-cells in MCD diet induced NASH liver of wild type mice. In the mutant animals these NASH associated changes in immune cell composition were less pronounced. Further, there were more γδ T-cells in the NASH liver of the null mice. Galectin-3 protein in the hepatic non-parenchymal cell fraction was strongly induced in MCD diet fed wild type but not mutant mice. Antioxidant enzymes declined in NASH liver with no differences between the genotypes. To identify the target cells responsive to SNTA loss in-vitro experiments were performed. In the human hepatic stellate cell line LX-2, SNTA did not regulate pro-fibrotic or antioxidant proteins like alpha-smooth muscle actin or catalase. Soluble galectin-3 was, however, reduced upon SNTA knock-down and increased upon SNTA overexpression. SNTA deficiency neither affected cell proliferation nor cell death of LX-2 cells. In the macrophage cell line RAW264.7 low SNTA indeed caused higher galectin-3 production whereas release of TNF and cell viability were normal. Moreover, SNTA had no effect on hepatocyte chemerin and CCL2 expression. Overall, SNTA loss improved NASH without causing major effects in macrophage, hepatocyte and hepatic stellate cell lines. SNTA null mice fed the MCD diet had less body weight loss and this seems to contribute to improved liver health of the mutant mice.
Subject(s)
CD8-Positive T-Lymphocytes/immunology , Calcium-Binding Proteins/deficiency , Galectin 3/metabolism , Liver/pathology , Macrophages/pathology , Membrane Proteins/deficiency , Muscle Proteins/deficiency , Non-alcoholic Fatty Liver Disease/immunology , Non-alcoholic Fatty Liver Disease/prevention & control , Actins/metabolism , Animals , Antioxidants/metabolism , Body Weight , Calcium-Binding Proteins/metabolism , Catalase/metabolism , Cell Line , Cell Proliferation , Cell Survival , Chemokine CCL2/metabolism , Chemokines/metabolism , Connective Tissue Growth Factor/metabolism , Fatty Acid Synthases/metabolism , Feeding Behavior , Heme Oxygenase-1/metabolism , Humans , Intercellular Signaling Peptides and Proteins/metabolism , Interleukin-6/metabolism , L-Lactate Dehydrogenase/metabolism , Macrophages/metabolism , Male , Membrane Proteins/metabolism , Mice, Inbred C57BL , Muscle Proteins/metabolism , Non-alcoholic Fatty Liver Disease/pathology , Superoxide Dismutase/metabolism , Tumor Necrosis Factor-alpha/metabolismABSTRACT
The scaffold protein alpha-syntrophin (SNTA) is a component of the dystrophin glycoprotein complex and has been comprehensively studied in skeletal muscle and adipocytes. SNTA is further expressed in the liver where its biological role remains unclear. Unpublished data from our group suggested that SNTA deficiency is associated with altered tubulin alpha 8 (TUBA8) levels in fat. TUBA8 is highly expressed in different cell lines including hepatoma cells, and here we analyzed whether SNTA has a role herein. In Hepa1-6 cells, TUBA8 protein levels were increased upon SNTA knock down and were reduced upon overexpression of SNTA. This regulation was not identified when analyzing mRNA expression. In the liver of SNTA-deficient mice, TUBA8 protein was higher compared to the respective wild-type controls while RNA expression was even suppressed. Using the HaloTag platform, TUBA8 was found to form a complex with SNTA in Hepa1-6 cells. In the hepatic stellate cell line LX-2, the lack or overexpression of SNTA did, however, not change TUBA8 protein expression. SNTA and TUBA8 are described to regulate cell proliferation. Yet, knock down of SNTA did neither affect proliferation nor viability of Hepa1-6 cells. The present study shows that SNTA protein levels are inversely related to TUBA8 protein expression in the hepatocyte cell line Hepa1-6
Subject(s)
Humans , Animals , Male , Mice , Calcium-Binding Proteins/metabolism , Gene Expression Regulation , Hepatocytes/metabolism , Membrane Proteins/metabolism , Muscle Proteins/metabolism , Tubulin/metabolism , 3T3-L1 Cells , Calcium-Binding Proteins/antagonists & inhibitors , Calcium-Binding Proteins/genetics , Cell Line, Tumor , Cell Proliferation , Hepatocytes/cytology , Immunoprecipitation , Membrane Proteins/genetics , Mice, Inbred C57BL , Mice, KnockoutABSTRACT
The scaffold protein alpha-syntrophin (SNTA) is a component of the dystrophin glycoprotein complex and has been comprehensively studied in skeletal muscle and adipocytes. SNTA is further expressed in the liver where its biological role remains unclear. Unpublished data from our group suggested that SNTA deficiency is associated with altered tubulin alpha 8 (TUBA8) levels in fat. TUBA8 is highly expressed in different cell lines including hepatoma cells, and here we analyzed whether SNTA has a role herein. In Hepa1-6 cells, TUBA8 protein levels were increased upon SNTA knock down and were reduced upon overexpression of SNTA. This regulation was not identified when analyzing mRNA expression. In the liver of SNTA-deficient mice, TUBA8 protein was higher compared to the respective wild-type controls while RNA expression was even suppressed. Using the HaloTag platform, TUBA8 was found to form a complex with SNTA in Hepa1-6 cells. In the hepatic stellate cell line LX-2, the lack or overexpression of SNTA did, however, not change TUBA8 protein expression. SNTA and TUBA8 are described to regulate cell proliferation. Yet, knock down of SNTA did neither affect proliferation nor viability of Hepa1-6 cells. The present study shows that SNTA protein levels are inversely related to TUBA8 protein expression in the hepatocyte cell line Hepa1-6.
